Lillian Y Lai1, Mary K Oerline1, Megan E V Caram2,3, Phoebe A Tsao2,3, Samuel R Kaufman1, Brent K Hollenbeck1, Vahakn B Shahinian1,4. 1. Department of Urology, University of Michigan Medical School, Ann Arbor, MI, USA. 2. Veterans Affairs Health Services Research & Development, Center for Clinical Management and Research, VA Ann Arbor Healthcare System, Ann Arbor, MI, USA. 3. Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA. 4. Division of Nephrology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.
Abstract
BACKGROUND: Abiraterone and enzalutamide are the most common oral agents for the treatment of men with advanced prostate cancer. To understand their safety profiles in real-world settings, we examined the association between the use of abiraterone or enzalutamide and the risk of metabolic or cardiovascular adverse events while on treatment. METHODS: Men with advanced prostate cancer and their use of abiraterone or enzalutamide were identified in a 20% sample of the 2010-2017 national Medicare claims. The primary composite outcome was the occurrence of a major metabolic or cardiovascular adverse event, defined as an emergency room visit or hospitalization associated with a primary diagnosis of diabetes, hypertension, or cardiovascular disease. The secondary composite outcome was the occurrence of a minor metabolic or cardiovascular adverse event, defined as an outpatient visit associated with a primary diagnosis of the aforementioned conditions. Risks were assessed separately for abiraterone and enzalutamide using Cox regression. All statistical tests were 2-sided. RESULTS: Compared with men not receiving abiraterone, men receiving abiraterone were at increased risk of both a major composite adverse event (hazard ratio [HR] = 1.77, 95% confidence interval [CI] = 1.53 to 2.05; P < .001) and a minor composite adverse event (HR = 1.24, 95% CI = 1.05 to 1.47; P = .01). Compared with men not receiving enzalutamide, men receiving enzalutamide were at an increased risk of a major composite adverse event (HR = 1.22, 95% CI = 1.01 to 1.48; P = .04) but not a minor composite adverse event (HR = 1.04, 95% CI = 0.83 to 1.30; P = .75). CONCLUSION: Careful monitoring and management of men on abiraterone or enzalutamide through team-based approaches are critical.
BACKGROUND: Abiraterone and enzalutamide are the most common oral agents for the treatment of men with advanced prostate cancer. To understand their safety profiles in real-world settings, we examined the association between the use of abiraterone or enzalutamide and the risk of metabolic or cardiovascular adverse events while on treatment. METHODS: Men with advanced prostate cancer and their use of abiraterone or enzalutamide were identified in a 20% sample of the 2010-2017 national Medicare claims. The primary composite outcome was the occurrence of a major metabolic or cardiovascular adverse event, defined as an emergency room visit or hospitalization associated with a primary diagnosis of diabetes, hypertension, or cardiovascular disease. The secondary composite outcome was the occurrence of a minor metabolic or cardiovascular adverse event, defined as an outpatient visit associated with a primary diagnosis of the aforementioned conditions. Risks were assessed separately for abiraterone and enzalutamide using Cox regression. All statistical tests were 2-sided. RESULTS: Compared with men not receiving abiraterone, men receiving abiraterone were at increased risk of both a major composite adverse event (hazard ratio [HR] = 1.77, 95% confidence interval [CI] = 1.53 to 2.05; P < .001) and a minor composite adverse event (HR = 1.24, 95% CI = 1.05 to 1.47; P = .01). Compared with men not receiving enzalutamide, men receiving enzalutamide were at an increased risk of a major composite adverse event (HR = 1.22, 95% CI = 1.01 to 1.48; P = .04) but not a minor composite adverse event (HR = 1.04, 95% CI = 0.83 to 1.30; P = .75). CONCLUSION: Careful monitoring and management of men on abiraterone or enzalutamide through team-based approaches are critical.
Authors: Maha Hussain; Karim Fizazi; Fred Saad; Per Rathenborg; Neal Shore; Ubirajara Ferreira; Petro Ivashchenko; Eren Demirhan; Katharina Modelska; Andrew Krivoshik; Cora N Sternberg Journal: N Engl J Med Date: 2018-06-28 Impact factor: 91.245
Authors: Neal D Shore; Daniel Saltzstein; Paul Sieber; Bryan Mehlhaff; Lawrence Gervasi; Jennifer Phillips; Yu-Ning Wong; Huiling Pei; Tracy McGowan Journal: Clin Genitourin Cancer Date: 2019-08-06 Impact factor: 2.872
Authors: M Alyamani; J Li; M Patel; S Taylor; F Nakamura; M Berk; C Przybycin; E M Posadas; R A Madan; J L Gulley; B Rini; J A Garcia; E A Klein; N Sharifi Journal: Ann Oncol Date: 2020-02-11 Impact factor: 32.976
Authors: Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono Journal: N Engl J Med Date: 2012-08-15 Impact factor: 91.245
Authors: A V Diez Roux; S S Merkin; D Arnett; L Chambless; M Massing; F J Nieto; P Sorlie; M Szklo; H A Tyroler; R L Watson Journal: N Engl J Med Date: 2001-07-12 Impact factor: 91.245
Authors: Karim Fizazi; Kim N Chi; Johann S de Bono; Leonard G Gomella; Kurt Miller; Dana E Rathkopf; Charles J Ryan; Howard I Scher; Neal D Shore; Peter De Porre; Anil Londhe; Tracy McGowan; Nonko Pelhivanov; Robert Charnas; Mary B Todd; Bruce Montgomery Journal: Eur Urol Date: 2016-03-07 Impact factor: 20.096
Authors: Andrew J Armstrong; Russell Z Szmulewitz; Daniel P Petrylak; Jeffrey Holzbeierlein; Arnauld Villers; Arun Azad; Antonio Alcaraz; Boris Alekseev; Taro Iguchi; Neal D Shore; Brad Rosbrook; Jennifer Sugg; Benoit Baron; Lucy Chen; Arnulf Stenzl Journal: J Clin Oncol Date: 2019-07-22 Impact factor: 44.544